News &amp; Updates

Though safe and without notable side effects, ginseng extract does not seem to yield significant cardiovascular benefit in patients with severe atherosclerosis, a new study has found.

Product Highlight - RASEC

Racecadotril 30 mg powder for oral suspension

Product Highlight - GESTIVIA

Saccharomyces boulardii, fibersol-2, inulin, isomalto-oligosaccharide, magnesium stearate cap

Product Highlight - HUMER STERILE ISOTONIC SEA WATER SOLUTION

Isotonic seawater solution

Sotrovimab may reduce COVID-19 disease progression

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

23 Nov 2021

Hyperglycaemic infants at risk of retinopathy of prematurity

Infants with hyperglycaemia are at an increased risk of having retinopathy of prematurity (ROP), a recent study has found. Meanwhile, no such effect was observed for serum levels of glycated albumin (GlyA).

Dupilumab benefits in EoE sustained through 52 weeks

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.

High-dose corticosteroid good for maintenance treatment in eosinophilic esophagitis

Eosinophilic esophagitis patients are likely to experience histological relapse despite ongoing treatment with swallowed topical corticosteroid (STC), but relapse occurs later with high- than with low-dose STC without any increase in side effects, a study has found.

Hypertension-related CVD rates rise from 1990 to 2019

For three decades, hypertension-related cardiovascular disease (CVD) burden in young adults has substantially rose, with spatiotemporal and sexual heterogeneity, according to a study. Middle-income countries bear the heaviest burden, particularly men.

23 Nov 2021

Implantable cardioverter-defibrillators prevent death in patients with long QT syndrome

Use of implantable cardioverter-defibrillators (ICDs) results in a reduced risk of all-cause mortality, all-cause mortality before age 50 years, and sudden cardiac death in patients with long QT syndrome (LQTS), according to a study.